Evolving role of 5-alpha reductase inhibitors in chemoprevention.
White
Wesley M
WM
Kim
Edward D
ED
D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D001378:Azasteroids / Q000627:therapeutic use; D000068538:Dutasteride; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011322:Primary Prevention / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000517:prevention & control*
D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D018120:Finasteride; D000068538:Dutasteride
J Urol. 2009 Apr;181(4):1642-57
19249063
J Clin Oncol. 2009 Jul 10;27(20):e22; author reply e23
19487370
Cancer. 2008 Mar 1;112(5):1058-65
18186497
N Engl J Med. 2010 Apr 1;362(13):1192-202
20357281
N Engl J Med. 2003 Jul 24;349(4):366-81
12878745
Urol Clin North Am. 2010 Feb;37(1):11-21, Table of Contents
20152515
N Engl J Med. 2003 Jul 17;349(3):215-24
12824459
Cancer Prev Res (Phila). 2008 Aug;1(3):167-73
19138952
J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33
16912265